抗体開発適性評価

Biointron’s Antibody Developability Assessment involves assays which evaluate critical properties including protein quality, thermal stability, self-interaction, hydrophobicity, radium analysis, positive charge tendency, charge heterogeneity, and non-specific binding. Each analysis has a timeline of three to five days.

The quality and effectiveness of Biointron’s Antibody Developability Assessment are ensured through a combination of advanced technologies, expert analysis, and a data-driven workflow. All assays are performed under rigorous conditions. Biointron’s experienced scientific team interprets the results, provides detailed reports, and offers protein engineering support when needed, ensuring that only the most promising candidates move forward, thus reducing development risks and accelerating CMC readiness.

Assessing developability early helps identify issues related to homogeneity, stability, solubility, and specificity that could lead to ailures in efficacy, safety, or manufacturability during later stages. Early screening reduces development risks, shortens timelines, and avoids costly setbacks during CMC or clinical trials.

By identifying potential liabilities such as instability, aggregation, or immunogenicity early on, Biointron helps prioritize robust ntibody candidates. This reduces the chance of costly failures during clinical development or manufacturing, supporting a smoother, faster path to IND and commercialization.

Our Developability Assessment complements our other antibody optimization services by evaluating the manufacturability and stability of candidates that have already undergone humanization or affinity maturation. After antibodies are engineered for improved affinity or reduced immunogenicity, developability testing helps ensure those optimized sequences maintain favorable biophysical properties (such as solubility, stability, and specificity)

Modifying an antibody may introduce new structural elements that affect key properties like stability, solubility, and antigen-binding activity. Therefore, it's crucial to assess the developability of modified antibodies early in the development process. This helps identify potential issues with manufacturability or therapeutic performance. Additionally, such modifications often require new analytical tools and production methods, which an further influence the developability and scalability of the final product.

Key determinants include homogeneity, stability, solubility, and specificity. Antibodies with issues such as visible particles, poor expression yield, low thermal stability, or a tendency to aggregate often signal high risk. Post-translational modifications in the ntigen-binding regions (e.g., deamidation, isomerization, or oxidation) can also undermine potency and safety. Identifying these iabilities early is critical for candidate selection.

At the discovery stage, assessments are rapid and high-throughput, consuming small amounts of material to compare many candidates side by side. The goal is to flag risks early and select the most promising molecules for advancement.

By contrast, CMC-stage studies are more comprehensive, requiring larger material quantities and extensive testing for formulation, stress stability, and manufacturing robustness. Early assessment avoids costly surprises at this later, resource-intensive stage.

Yes. Many liabilities can be mitigated through protein engineering (e.g., removing high-risk motifs, reducing hydrophobic patches, optimizing charge balance), or through formulation strategies such as buffer optimization or excipient use. Early detection makes these fixes faster and less costly compared to adjustments later in development.